## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Basta NE, Mahmoud AAF, Wolfson J, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med 2016;375:220-8. DOI: 10.1056/NEJMoa1514866

## Supplementary Appendix

## **Table of Contents**

## I. Table S1: Seropositivity and GMTs against the outbreak strain by vaccination schedule

	n	Immunity against the MenB Outbreak Strain (PorA P1.5-1,2.2; fHbp 1.276; NHBA p0002; NadA-)	
		% hSBA≥4 (95% CI)	GMT (95% CI)
2 Doses 4CMenB	559	67.4	7.8
(All Schedules)		(63.4 -71.3)	(7.0-8.8)
2 Doses 4CMenB	19	78.9	20.4
(December and January)		(54.4-93.5)	(8.2-50.9)
2 Doses 4CMenB	499	66.1	7.6
(December and February)		(61.8-70.3)	(6.7-8.5)
2 Doses 4CMenB	27	92.6	9.8
(December and March)		(75.7-99.1)	(6.4-15.1)
1 Dose 4CMenB	21	57.1	5.2
(All Schedules)		(34.0-78.2)	(2.8-9.7)
1 Dose 4CMenB	17	58.8	5.4
(December)		(32.9-81.6)	(2.5-11.7)
Unvaccinated	19	21.1 (6.1-45.6)	2.8 (2.3-3.5)

hSBA – Serum bactericidal antibody using human complement; CI – Confidence interval; GMT – Geometric mean titer